The Resource Follow-on biologics : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007, (electronic resource)

Follow-on biologics : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007, (electronic resource)

Label
Follow-on biologics : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007
Title
Follow-on biologics
Title remainder
hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007
Creator
Subject
Genre
Language
eng
Member of
Cataloging source
GPO
Government publication
federal national government publication
Index
no index present
Literary form
non fiction
Nature of contents
bibliography
http://bibfra.me/vocab/lite/organizationName
United States
Series statement
S. hrg.
Series volume
110-375
http://library.link/vocab/subjectName
  • Pharmaceutical biotechnology
  • Pharmaceutical biotechnology
  • Pharmaceutical technology
  • Drug development
Label
Follow-on biologics : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007, (electronic resource)
Instantiates
Publication
Note
  • Title from title screen (viewed on Nov. 17, 2008)
  • Paper version available for sale by the Supt. of Docs., U.S. G.P.O
Bibliography note
Includes bibliographical references
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
black and white
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Extent
1 electronic text (iv, 78 pages)
Form of item
online
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Other physical details
HTML, digital, PDF file
http://library.link/vocab/ext/overdrive/overdriveId
552-070-37953-1
Specific material designation
remote
System details
Mode of access: Internet from the GPO Access web site. Addresses as of 11/17/08: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110%5Fsenate%5Fhearings&docid=f:34053.wais (text version); http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110%5Fsenate%5Fhearings&docid=f:34053.pdf (PDF version); current access is available via PURLs
Label
Follow-on biologics : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007, (electronic resource)
Publication
Note
  • Title from title screen (viewed on Nov. 17, 2008)
  • Paper version available for sale by the Supt. of Docs., U.S. G.P.O
Bibliography note
Includes bibliographical references
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
black and white
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Extent
1 electronic text (iv, 78 pages)
Form of item
online
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Other physical details
HTML, digital, PDF file
http://library.link/vocab/ext/overdrive/overdriveId
552-070-37953-1
Specific material designation
remote
System details
Mode of access: Internet from the GPO Access web site. Addresses as of 11/17/08: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110%5Fsenate%5Fhearings&docid=f:34053.wais (text version); http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110%5Fsenate%5Fhearings&docid=f:34053.pdf (PDF version); current access is available via PURLs

Library Locations

    • Biddle Law LibraryBorrow it
      3400 Chestnut Street, Philadelphia, Pennsylvania, 19104, US
      39.954941 -75.193362
Processing Feedback ...